3 results match your criteria: "Willamette Valley Cancer Center.[Affiliation]"
Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825.
Neuro Oncol
November 2024
Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Article Synopsis
- Glioblastoma (GBM) is a severe brain cancer that can lead to toxic side effects during treatment, prompting this study to explore genetic and clinical factors associated with vascular toxicities such as thrombosis and hypertension in patients.
- A total of 591 Non-Hispanic White GBM patients were analyzed, with 62 experiencing thrombosis and 59 hypertension, revealing that hypertensive patients had improved survival rates compared to those without hypertension.
- The study found that genetic factors significantly predicted hypertension better than clinical data alone, while corticosteroid use was identified as a notable risk factor for thrombosis, suggesting a need for further research into these associations in cancer treatments.
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
J Neurooncol
December 2021
University Hospitals, Cleveland, OH, USA.
Background/purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be an important prognostic factor for GBM. The purpose of this study was to develop and independently validate sex-specific nomograms for estimation of individualized GBM survival probabilities using data from 2 independent NRG Oncology clinical trials.
View Article and Find Full Text PDF